The latest price target for Sangamo Therapeutics (NASDAQ:SGMO) was reported by RBC Capital on March 18, 2025. The analyst firm set a price target for $2.00 expecting SGMO to rise to within 12 months (a possible 139.75% upside). 18 analyst firms have reported ratings in the last year.

The latest analyst rating for Sangamo Therapeutics (NASDAQ:SGMO) was provided by RBC Capital, and Sangamo Therapeutics reiterated their sector perform rating.

The last upgrade for Sangamo Therapeutics Inc happened on February 27, 2023 when Wedbush raised their price target to $16. Wedbush previously had a neutral for Sangamo Therapeutics Inc.

The last downgrade for Sangamo Therapeutics Inc happened on November 7, 2023 when Truist Securities changed their price target from N/A to N/A for Sangamo Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Sangamo Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Sangamo Therapeutics was filed on March 18, 2025 so you should expect the next rating to be made available sometime around March 18, 2026.

While ratings are subjective and will change, the latest Sangamo Therapeutics (SGMO) rating was a reiterated with a price target of $2.00 to $2.00. The current price Sangamo Therapeutics (SGMO) is trading at is $0.83, which is out of the analyst’s predicted range.